troglitazone has been researched along with Angiogenesis, Pathologic in 6 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation." | 7.74 | Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008) |
| "To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation." | 3.74 | Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, JC | 1 |
| Obert, LA | 1 |
| Koza-Taylor, P | 1 |
| Coskran, TM | 1 |
| Opsahl, AC | 1 |
| Ziemek, D | 1 |
| Roy, M | 1 |
| Qian, J | 1 |
| Lawton, MP | 1 |
| Criswell, KA | 1 |
| Qiao, L | 1 |
| Li, GH | 1 |
| Dai, Y | 1 |
| Wang, J | 1 |
| Li, Z | 1 |
| Zou, B | 1 |
| Gu, Q | 1 |
| Ma, J | 1 |
| Pang, R | 1 |
| Lan, HY | 1 |
| Wong, BC | 1 |
| Huang, H | 1 |
| Campbell, SC | 1 |
| Bedford, DF | 1 |
| Nelius, T | 1 |
| Veliceasa, D | 1 |
| Shroff, EH | 1 |
| Henkin, J | 1 |
| Schneider, A | 1 |
| Bouck, N | 1 |
| Volpert, OV | 1 |
| Keshamouni, VG | 1 |
| Arenberg, DA | 1 |
| Reddy, RC | 1 |
| Newstead, MJ | 1 |
| Anthwal, S | 1 |
| Standiford, TJ | 1 |
| Jin, M | 1 |
| Matsumoto, S | 1 |
| Dewa, Y | 1 |
| Nishimura, J | 1 |
| Saekusa, Y | 1 |
| Hasumi, K | 1 |
| Mitsumori, K | 1 |
| Chung, C | 1 |
| Doll, JA | 1 |
| Stellmach, VM | 1 |
| Gonzales, J | 1 |
| Surapureddi, S | 1 |
| Cornwell, M | 1 |
| Reddy, JK | 1 |
| Crawford, SE | 1 |
6 other studies available for troglitazone and Angiogenesis, Pathologic
| Article | Year |
|---|---|
From the Cover: Fenretinide, Troglitazone, and Elmiron Add to Weight of Evidence Support for Hemangiosarcoma Mode-of-Action From Studies in Mice.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Fenr | 2018 |
Gene expression profile in colon cancer cells with respect to XIAP expression status.
Topics: Apoptosis; Blotting, Western; Cell Proliferation; Chromans; Colonic Neoplasms; Gene Expression Profi | 2009 |
Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.
Topics: Angiogenesis Inhibitors; CD36 Antigens; Cells, Cultured; Chromans; Drug Interactions; Endothelium, V | 2004 |
PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer.
Topics: Amino Acid Motifs; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Ce | 2005 |
Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane.
Topics: Angiogenic Proteins; Animals; Body Weight; Carcinogens; Cell Proliferation; Chromans; Female; Gene E | 2008 |
Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cell Movement; Chromans; Clofibric Acid; Endothelium, Vascu | 2008 |